Ceapro Competitors

Novoheart (CVE:NVH) and Ceapro (CVE:CZO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership and profitability.

Analyst Ratings

This is a breakdown of recent ratings for Novoheart and Ceapro, as reported by MarketBeat.

Profitability

This table compares Novoheart and Ceapro's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Novoheart and Ceapro's gross revenue, earnings per share and valuation.

Ceapro has higher revenue and earnings than Novoheart. Novoheart is trading at a lower price-to-earnings ratio than Ceapro, indicating that it is currently the more affordable of the two stocks.

Summary

Ceapro beats Novoheart on 4 of the 5 factors compared between the two stocks.

Microbix Biosystems (TSE:MBX) and Ceapro (CVE:CZO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Microbix Biosystems and Ceapro, as provided by MarketBeat.

Profitability

This table compares Microbix Biosystems and Ceapro's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Microbix Biosystems and Ceapro's top-line revenue, earnings per share (EPS) and valuation.

Ceapro has higher revenue and earnings than Microbix Biosystems. Microbix Biosystems is trading at a lower price-to-earnings ratio than Ceapro, indicating that it is currently the more affordable of the two stocks.

Summary

Ceapro beats Microbix Biosystems on 4 of the 5 factors compared between the two stocks.

Ceapro (CVE:CZO) and Pediapharm (CVE:PDP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, analyst recommendations, profitability, earnings and risk.

Earnings and Valuation

This table compares Ceapro and Pediapharm's gross revenue, earnings per share (EPS) and valuation.

Ceapro has higher revenue and earnings than Pediapharm. Pediapharm is trading at a lower price-to-earnings ratio than Ceapro, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Ceapro and Pediapharm, as reported by MarketBeat.

Profitability

This table compares Ceapro and Pediapharm's net margins, return on equity and return on assets.

Summary

Ceapro beats Pediapharm on 4 of the 5 factors compared between the two stocks.

Ceapro (CVE:CZO) and Sirona Biochem (CVE:SBM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, earnings, profitability, valuation, risk, institutional ownership and dividends.

Profitability

This table compares Ceapro and Sirona Biochem's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Ceapro and Sirona Biochem's top-line revenue, earnings per share and valuation.

Ceapro has higher revenue and earnings than Sirona Biochem. Sirona Biochem is trading at a lower price-to-earnings ratio than Ceapro, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for Ceapro and Sirona Biochem, as reported by MarketBeat.

Summary

Ceapro beats Sirona Biochem on 4 of the 5 factors compared between the two stocks.

Ceapro (CVE:CZO) and ProMIS Neurosciences (TSE:PMN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Analyst Recommendations

This is a breakdown of current recommendations for Ceapro and ProMIS Neurosciences, as provided by MarketBeat.

Profitability

This table compares Ceapro and ProMIS Neurosciences' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Ceapro and ProMIS Neurosciences' revenue, earnings per share (EPS) and valuation.

Ceapro has higher revenue and earnings than ProMIS Neurosciences. ProMIS Neurosciences is trading at a lower price-to-earnings ratio than Ceapro, indicating that it is currently the more affordable of the two stocks.

Summary

Ceapro beats ProMIS Neurosciences on 4 of the 5 factors compared between the two stocks.

Ceapro (CVE:CZO) and Covalon Technologies (CVE:COV) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, risk, institutional ownership and dividends.

Profitability

This table compares Ceapro and Covalon Technologies' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Ceapro and Covalon Technologies' revenue, earnings per share and valuation.

Ceapro has higher earnings, but lower revenue than Covalon Technologies. Covalon Technologies is trading at a lower price-to-earnings ratio than Ceapro, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Ceapro and Covalon Technologies, as reported by MarketBeat.

Summary

Ceapro beats Covalon Technologies on 4 of the 5 factors compared between the two stocks.